First approved for adults in 2022, the therapy is now cleared for adults and pediatric patients weighing 66 lbs or more with symptomatic obstructive hypertrophic cardiomyopathy.
News|Articles|December 10, 2007
This breast cancer drug is first in new class of chemo agents
The FDA has approved Ixabepilone (Ixempra) as a monotherapy and in combination with capecitabine (Xeloda) for patients with metastic or locally advanced breast cancer.
Advertisement
Advertisement
Related to this article
The once daily tablet is expected to reach US patients in October 2026.
The label expansion adds patients 12 years of age and older to the once daily alopecia areata indication.
This episode offers a detailed look into the FDA’s recent PCAC meeting and what the future of peptide compounding could lead to for pharmacy professionals.
Eli Lilly’s new indication helps improve medication delivery for adults with type 2 diabetes, reducing annual injections by over 300.
The update adds efficacy and safety data on adults newly diagnosed with pulmonary arterial hypertension.
What pharmacy technicians say would actually make them feel seen on World Pharmacy Technician Day, and the other 364 days of the year.
The analysis is not a head-to-head trial, and the weight loss gap reached statistical significance under 1 of 2 estimands.
Advertisement
Advertisement